跳至主要内容
临床试验/CTRI/2023/11/059369
CTRI/2023/11/059369招募中Unknown

The Gamma-glutamyl transpeptidase to platelet ratio for non invasive assessment of liver fibrosis in patients with chronic Hepatitis B,Hepatitis C and non alcoholic fatty liver disease - NI

Dr Eshan Taneja0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • Patients at risk of parenchymal liver disease undergoing Fibroscan as part of standard of care With main focus on known etiology of NAFLD ,Hepatitis B ,Hepatitis C who are able to give written informed consent

排除标准

  • DERRANGED PLATELET COUNT ( <1,00,000 or >3,50,000)
  • Known case of cholestasis
  • Alcoholic Liver Disease ( 40-80 g/day of alcohol consumption in me and >20g/day in women)
  • Patient with Cardiac Pacemaker
  • Technical difficulty (Ascites, Pregnancy)

研究者

发起方
Dr Eshan Taneja

相似试验